http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 15:48:36 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Omeros+%28OMER%29+call+put+ratio+1+call+to+2.4+put+as+share+price+up+4.9%25/26768039.html <p>Omeros (NASDAQ: OMER) 30-day option implied volatility is at 104; compared to its 52-week range of 60 to 265. Call put ratio 1 call to 2.4 put as share price up 4.9%.</p> http://www.streetinsider.com/Options/Omeros+%28OMER%29+call+put+ratio+1+call+to+2.4+put+as+share+price+up+4.9%25/26768039.html Tue, 14 Jul 2026 15:48:36 -0400 OMER http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OMEROS+CORP+++++++++++++++For%3A+Jul+02/26733233.html si-local-file:///var/storage/secattach/20260706/26733233.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OMEROS+CORP+++++++++++++++For%3A+Jul+02/26733233.html Mon, 06 Jul 2026 08:30:00 -0400 O.00024645 OMER http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OMEROS+CORP+++++++++++++++For%3A+Jul+02/26733233.html si-local-file:///var/storage/secattach/20260706/26733233.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++OMEROS+CORP+++++++++++++++For%3A+Jul+02/26733233.html Mon, 06 Jul 2026 08:30:00 -0400 O.00024645 OMER http://www.streetinsider.com/Analyst+PT+Change/Omeros+Corp.+%28OMER%29+PT+Lowered+to+%2433+at+H.C.+Wainwright/26701956.html (Updated - June 29, 2026 7:07 AM EDT) <p>H.C. Wainwright analyst Brandon Folkes lowered the price target on Omeros Corp. (NASDAQ: OMER) to $33.00 (from $40.00) while maintaining a Buy rating.</p><p>The analyst commented: "OMER’s negative CHMP opinion for YARTEMLEA is disappointing and likely creates a near-term overhang, but we do not view it as thesis-breaking. We are removing the EU opportunity from our model, lowering our exit multiple, and increasing go-forward R&D spend, which takes our price target to $33 from $40; however, the EU removal itself only reduces our valuation by approximately $2/share, with the U.S. YARTEMLEA launch still representing http://www.streetinsider.com/Analyst+PT+Change/Omeros+Corp.+%28OMER%29+PT+Lowered+to+%2433+at+H.C.+Wainwright/26701956.html Mon, 29 Jun 2026 07:07:29 -0400 OMER http://www.streetinsider.com/Analyst+Comments/Omeros+Corp.+%28OMER%29+PT+Lowered+to+%2433+at+H.C.+Wainwright/26701956.html (Updated - June 29, 2026 7:07 AM EDT) <p>H.C. Wainwright analyst Brandon Folkes lowered the price target on Omeros Corp. (NASDAQ: OMER) to $33.00 (from $40.00) while maintaining a Buy rating.</p><p>The analyst commented: "OMER’s negative CHMP opinion for YARTEMLEA is disappointing and likely creates a near-term overhang, but we do not view it as thesis-breaking. We are removing the EU opportunity from our model, lowering our exit multiple, and increasing go-forward R&D spend, which takes our price target to $33 from $40; however, the EU removal itself only reduces our valuation by approximately $2/share, with the U.S. YARTEMLEA launch still representing http://www.streetinsider.com/Analyst+Comments/Omeros+Corp.+%28OMER%29+PT+Lowered+to+%2433+at+H.C.+Wainwright/26701956.html Mon, 29 Jun 2026 07:07:29 -0400 OMER http://www.streetinsider.com/Corporate+News/EMA+panel+issues+negative+opinion+on+Omeros+narsoplimab+application/26695339.html <p>Omeros Corporation (Nasdaq: OMER) said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the company's marketing authorization application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).</p><p>The decision followed an oral explanation meeting at which Omeros presented its position alongside four international experts in hematopoietic cell transplantation. Omeros said it intends to request a re-examination of the CHMP opinion and will seek review by an Ad Hoc Expert Group, an independent panel of external scientific and clinical experts to be convened by the EMA.</p><p>Narsoplimab, sold under http://www.streetinsider.com/Corporate+News/EMA+panel+issues+negative+opinion+on+Omeros+narsoplimab+application/26695339.html Fri, 26 Jun 2026 08:30:57 -0400 OMER http://www.streetinsider.com/FDA/EMA+panel+issues+negative+opinion+on+Omeros+narsoplimab+application/26695339.html <p>Omeros Corporation (Nasdaq: OMER) said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the company's marketing authorization application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).</p><p>The decision followed an oral explanation meeting at which Omeros presented its position alongside four international experts in hematopoietic cell transplantation. Omeros said it intends to request a re-examination of the CHMP opinion and will seek review by an Ad Hoc Expert Group, an independent panel of external scientific and clinical experts to be convened by the EMA.</p><p>Narsoplimab, sold under http://www.streetinsider.com/FDA/EMA+panel+issues+negative+opinion+on+Omeros+narsoplimab+application/26695339.html Fri, 26 Jun 2026 08:30:57 -0400 OMER http://www.streetinsider.com/Hot+Corp.+News/EMA+panel+issues+negative+opinion+on+Omeros+narsoplimab+application/26695339.html <p>Omeros Corporation (Nasdaq: OMER) said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the company's marketing authorization application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).</p><p>The decision followed an oral explanation meeting at which Omeros presented its position alongside four international experts in hematopoietic cell transplantation. Omeros said it intends to request a re-examination of the CHMP opinion and will seek review by an Ad Hoc Expert Group, an independent panel of external scientific and clinical experts to be convened by the EMA.</p><p>Narsoplimab, sold under http://www.streetinsider.com/Hot+Corp.+News/EMA+panel+issues+negative+opinion+on+Omeros+narsoplimab+application/26695339.html Fri, 26 Jun 2026 08:30:57 -0400 OMER http://www.streetinsider.com/Hot+FDA+News/EMA+panel+issues+negative+opinion+on+Omeros+narsoplimab+application/26695339.html <p>Omeros Corporation (Nasdaq: OMER) said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the company's marketing authorization application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).</p><p>The decision followed an oral explanation meeting at which Omeros presented its position alongside four international experts in hematopoietic cell transplantation. Omeros said it intends to request a re-examination of the CHMP opinion and will seek review by an Ad Hoc Expert Group, an independent panel of external scientific and clinical experts to be convened by the EMA.</p><p>Narsoplimab, sold under http://www.streetinsider.com/Hot+FDA+News/EMA+panel+issues+negative+opinion+on+Omeros+narsoplimab+application/26695339.html Fri, 26 Jun 2026 08:30:57 -0400 OMER http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Press+Releases/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html <p> SEATTLE--(BUSINESS WIRE)-- <b>Omeros Corporation (Nasdaq: OMER) </b>announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization application (MAA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). </p><p> Following an oral explanation meeting with the CHMP held this week, at which Omeros presented its position together with four international experts in hematopoietic cell transplantation, Omeros was informed that the CHMP has adopted a negative opinion on the MAA for narsoplimab in TA-TMA. </p><p> Omeros intends to request re-examination of http://www.streetinsider.com/Business+Wire/Omeros+Corporation+Announces+Update+on+European+Marketing+Authorization+Application+for+Narsoplimab+in+TA-TMA/26695318.html Fri, 26 Jun 2026 08:30:00 -0400 A.06822034 A.31066700 O.00024645 O.20026344 O.22422661 OMER http://www.streetinsider.com/Investing/Omeros+stock+tumbles+after+EU+panel+rejects+Yartemlea/26694953.html <p>Investing.com -- Omeros Corporation (NASDAQ:OMER) fell 14% Friday morning after the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion for Yartemlea.</p><p>The CHMP recommended against approval of Yartemlea (narsoplimab) for the treatment of adults and children from two years of age with haematopoietic stem cell transplant-associated thrombotic microangiopathy. Thrombotic microangiopathy is a serious and potentially life-threatening complication following HSCT, a procedure where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow that produces healthy cells.</p><p>The committee also adopted negative opinions for two other medicines: Tacquell (autologous melanoma-derived http://www.streetinsider.com/Investing/Omeros+stock+tumbles+after+EU+panel+rejects+Yartemlea/26694953.html Fri, 26 Jun 2026 07:13:04 -0400 OMER http://www.streetinsider.com/FDA/Omeros+stock+tumbles+after+EU+panel+rejects+Yartemlea/26694953.html <p>Investing.com -- Omeros Corporation (NASDAQ:OMER) fell 14% Friday morning after the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion for Yartemlea.</p><p>The CHMP recommended against approval of Yartemlea (narsoplimab) for the treatment of adults and children from two years of age with haematopoietic stem cell transplant-associated thrombotic microangiopathy. Thrombotic microangiopathy is a serious and potentially life-threatening complication following HSCT, a procedure where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow that produces healthy cells.</p><p>The committee also adopted negative opinions for two other medicines: Tacquell (autologous melanoma-derived http://www.streetinsider.com/FDA/Omeros+stock+tumbles+after+EU+panel+rejects+Yartemlea/26694953.html Fri, 26 Jun 2026 07:13:04 -0400 OMER http://www.streetinsider.com/Trader+Talk/Omeros+stock+tumbles+after+EU+panel+rejects+Yartemlea/26694953.html <p>Investing.com -- Omeros Corporation (NASDAQ:OMER) fell 14% Friday morning after the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion for Yartemlea.</p><p>The CHMP recommended against approval of Yartemlea (narsoplimab) for the treatment of adults and children from two years of age with haematopoietic stem cell transplant-associated thrombotic microangiopathy. Thrombotic microangiopathy is a serious and potentially life-threatening complication following HSCT, a procedure where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow that produces healthy cells.</p><p>The committee also adopted negative opinions for two other medicines: Tacquell (autologous melanoma-derived http://www.streetinsider.com/Trader+Talk/Omeros+stock+tumbles+after+EU+panel+rejects+Yartemlea/26694953.html Fri, 26 Jun 2026 07:13:04 -0400 OMER http://www.streetinsider.com/Hot+FDA+News/Omeros+stock+tumbles+after+EU+panel+rejects+Yartemlea/26694953.html <p>Investing.com -- Omeros Corporation (NASDAQ:OMER) fell 14% Friday morning after the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion for Yartemlea.</p><p>The CHMP recommended against approval of Yartemlea (narsoplimab) for the treatment of adults and children from two years of age with haematopoietic stem cell transplant-associated thrombotic microangiopathy. Thrombotic microangiopathy is a serious and potentially life-threatening complication following HSCT, a procedure where the patient's bone marrow is replaced by stem cells from a donor to form new bone marrow that produces healthy cells.</p><p>The committee also adopted negative opinions for two other medicines: Tacquell (autologous melanoma-derived http://www.streetinsider.com/Hot+FDA+News/Omeros+stock+tumbles+after+EU+panel+rejects+Yartemlea/26694953.html Fri, 26 Jun 2026 07:13:04 -0400 OMER